N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats

References

• Ahmed N, Tarannum S. 2009. Acetylcholinesterase activity in the brain of alloxan diabetic albino rats: presence of an inhibitor of this enzyme activity in the cerebral extract. Int J Diab Dev Ctries. 29:174.
   PubMed Web of Science ®Google Scholar
• Annunziata P, Cioni C, Santonini R, Paccagnini E. 2002. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol. 131:41–49.
   PubMed Web of Science ®Google Scholar
• Beal MF, Mazurek MF. 1987. Substance P-like immunoreactivity is reduced in Alzheimer’s disease cerebral cortex. Neurology. 37:1205.
   PubMed Web of Science ®Google Scholar
• Bouzas-Rodríguez J, Zarraga-Granados G, Del Rayo Sanchez-Carbente M, Rodríguez-Valentín R, Gracida X, Anell-Rendón D, Covarrubias L, Castro-Obregón S. 2012. The nuclear receptor NR4A1 induces a form of cell death dependent on autophagy in mammalian cells. PLoS One. 7:e46422.
   PubMed Web of Science ®Google Scholar
• Burns A, Iliffe S. 2009. Alzheimer’s disease. BMJ. 338:b158.
   PubMed Web of Science ®Google Scholar
• Caberlotto L, Hurd YL, Murdock P, Wahlin JP, Melotto S, Corsi M, Carletti R. 2003. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci. 17:1736–1746.
   PubMed Web of Science ®Google Scholar
• Caioli S, Curcio L, Pieri M, Antonini A, Marolda R, Severini C, Zona C. 2011. Substance P receptor activation induces downregulation of the AMPA receptor functionality in cortical neurons from a genetic model of Amyotrophic Lateral Sclerosis. Neurobiol Dis. 44:92–101.
   PubMed Web of Science ®Google Scholar
• Cramer H, Schaudt D, Rissler K, Strubel D, Warter J-M, Kuntzmann F. 1985. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. J Neurol. 232:346–351.
   PubMed Web of Science ®Google Scholar
• Daschil N, Kniewallner KM, Obermair GJ, Hutter-Paier B, Windisch M, Marksteiner J, Humpel C. 2015. L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model. Neurobiol Aging. 36:1333–1341.
   PubMed Web of Science ®Google Scholar
• Douglas SD, Leeman SE. 2011. Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 1217:83–95.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7:88–95.
   PubMed Web of Science ®Google Scholar
• Floresco SB, Seamans JK, Phillips AG. 1997. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J Neurosci. 7:1880–1890.
   Google Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. 1999. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 66:137–147.
   PubMed Web of Science ®Google Scholar
• Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, Lapointe N. 2003. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci USA. 100:10032–10037.
   PubMed Web of Science ®Google Scholar
• Glowinski J, Iversen LL. 1966. Regional studies of catecholamines in the rat brain‐I. J Neurochem. 13:655–669.
   PubMed Web of Science ®Google Scholar
• Herpfer I, Lieb K. 2003. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry. 4:56–63.
   PubMed Web of Science ®Google Scholar
• Johansson P, Almqvist EG, Wallin A, Johansson J-O, Andreasson U, Blennow K, Zetterberg H, Svensson J. 2015. Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer’s disease. Neurosci Lett. 609:58–62.
   PubMed Web of Science ®Google Scholar
• John J, Nampoothiri M, Kumar N, Mudgal J, Nampurath GK, Chamallamudi MR. 2015. Sesamol, a lipid lowering agent, ameliorates aluminium chloride induced behavioral and biochemical alterations in rats. Phcog Mag. 11:327.
   Google Scholar
• Kawahara M, Kato-Negishi M. 2011. Link between aluminum and the pathogenesis of Alzheimer’s disease: the integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis. 2011:276393.
   PubMedGoogle Scholar
• Khan KA, Kumar N, Nayak PG, Nampoothiri M, Shenoy RR, Krishnadas N, Rao CM, Mudgal J. 2013. Impact of caffeic acid on aluminium chloride-induced dementia in rats. J Pharm Pharmacol. 65:1745–1752.
   PubMed Web of Science ®Google Scholar
• Kimura T, Ishiguro K, Hisanaga S-I. 2014. Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci. 7:65.
   PubMed Web of Science ®Google Scholar
• Kowall N, Quigley B, Krause J, Lu F, Kosofsky B, Ferrante R. 1993. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul Pept. 46:174–185.
   PubMedGoogle Scholar
• Kumar S. 1998. Biphasic effect of aluminium on cholinergic enzyme of rat brain. Neurosci Lett. 248:121–123.
   PubMed Web of Science ®Google Scholar
• Kumar Prakash A, Kumar A. 2009. Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol. 61:1665–1672.
   PubMed Web of Science ®Google Scholar
• Li W, Fotinos A, Wu Q, Chen Y, Zhu Y, Baranov S, Tu Y, Zhou EW, Sinha B, Kristal BS. 2015. N-acetyl-L-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model. Neurobiol Dis. 80:93–103.
   PubMed Web of Science ®Google Scholar
• Liang K, Lin M-H, Tyan Y-M. 1992. Involvement of amygdala N-methyl-D-asparate receptors in long-term retention of an inhibitory avoidance response in rats. Chinese J Physiol. 36:47–56.
   Google Scholar
• Maheswari S, Venkatakrishna Murali R, Balaji R. 2014. Aluminium induced cholinotoxicity in zebra fish brain-A sequel of oxidative stress. Int J Adv Res. 2:322–335.
   Google Scholar
• Martinez AN, Philipp MT. 2016. Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J Neurol Neuromed. 1:29.
   PubMedGoogle Scholar
• Morris R. 1984. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 11:47–60.
   PubMed Web of Science ®Google Scholar
• Nampoothiri M, John J, Kumar N, Mudgal J, Nampurath GK, Chamallamudi MR. 2015. Modulatory role of simvastatin against aluminium chloride-induced behavioural and biochemical changes in rats. Behav Neurol. 2015:210169.
   PubMedGoogle Scholar
• Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K. 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 71:362–381.
   PubMed Web of Science ®Google Scholar
• Quigley B, Kowall N. 1991. Substance P-like immunoreactive neurons are depleted in Alzheimer’s disease cerebral cortex. Neuroscience. 41:41–60.
   PubMed Web of Science ®Google Scholar
• Rahman I, Kode A, Biswas SK. 2006. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 1:3159–3165.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Puertas R, Pazos A, Zarranz J, Pascual J. 1994. Selective cortical decrease of high-affinity choline uptake carrier in Alzheimer’s disease: an autoradiographic study using3H-hemicholinium-3. J Neural Transm Park Dis Dement Sect. 8:161–169.
   PubMedGoogle Scholar
• Rösler N, Wichart I, Jellinger K. 2001. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients. J Neural Transm. 108:231.
   PubMed Web of Science ®Google Scholar
• Rosso M, Munoz M, Berger M. 2012. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Sci World J. 2012:381434.
   Google Scholar
• Sánchez-Iglesias S, Soto-Otero R, Iglesias-Gonzalez J, Barciela-Alonso MC, Bermejo-Barrera P, Méndez-Álvarez E. 2007. Analysis of brain regional distribution of aluminium in rats via oral and intraperitoneal administration. J Trace Elem Med Biol. 21:31–34.
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Ackenheil M. 2002. The role of substance P in depression: therapeutic implications. Dialogues Clin Neurosci. 4:21.
   PubMedGoogle Scholar
• Sirianni AC, Jiang J, Zeng J, Mao LL, Zhou S, Sugarbaker P, Zhang X, Li W, Friedlander RM, Wang X. 2015. N‐acetyl‐l‐tryptophan, but not N‐acetyl‐d‐tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis. J Neurochem. 134:956–968.
   PubMed Web of Science ®Google Scholar
• Thornton E, Tran TT, Vink R. 2010. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett. 481:64–67.
   PubMed Web of Science ®Google Scholar
• Thornton E, Vink R. 2012. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One. 7:e34138.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu S, Pei Z, Drozda M, Stavrovskaya IG, Del Signore SJ, Cormier K, Shimony EM, Wang H, Ferrante RJ. 2008. Inhibitors of cytochrome c release with therapeutic potential for Huntington’s disease. J Neurosci. 28:9473–9485.
   PubMed Web of Science ®Google Scholar
• Zhang X. 2008. Neuropharmacological studies of Parkinson’s disease with some emphasis on serotonin transmission [thesis]. Solna, Sweden: Department of Physiology and Pharmacology, Institutionen för fysiologi och farmakologi.
   Google Scholar